This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Roche, Exelixis Skin Cancer Drug Delays Tumor Progression

An  experimental drug developed by Roche (RHHBY), licensed from Exelixis (EXEL), delayed tumor progression in previously untreated patients with a genetically mutated form of melanoma, or skin cancer, according to results from a phase III study announced by the  companies Monday. 

Based on the new data, Roche intends to seek FDA approval for the new melanoma drug, known as cobimetinib. If approved, Exelixis will co-market the drug in the U.S. and share in revenue and profits. 

Exelixis shares were up 12% to $3.72 in Monday pre-market trading. 

The phase III study enrolled patients with melanoma which carried a mutation in the BRAF V600 gene. The patients were then randomized to receive Roche's currently approved melanoma drug Zelboraf plus cobimetinib or Zelboraf plus a placebo. Detailed data are being kept under wraps for presentation at a medical meeting, but Roche said the study met its primary endpoint -- a statistically significant improvement in progression-free survival favoring the Zelboraf-cobitmetinib combination. 

Roche reported roughly $400 million in Zelboraf sales worldwide in 2013, including $138 million in U.S. sales. GlaxoSmithKline also sells two melanoma drugs -- Mekinist and Tafinlar -- which targets BRAF mutation-positive tumors. 

If cobimetinib is approved in the U.S. Exelixis will initially receive half of the U.S. profits (or losses) under terms of the marketing deal with Roche. That share of U.S. profit decreases as sales increase. Outside the U.S., Exelixis will receive low, double-digit royalties on sales from Roche. 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 17,891.81 +118.17 0.66%
S&P 500 2,080.14 +14.84 0.72%
NASDAQ 4,814.1070 +38.7490 0.81%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs